This IP is significant advancement in cancer therapy, specifically targeting neuroblastoma—a tumor commonly found in children. This innovative oncolytic virus has been engineered to improve immune recognition of neuroblastoma antigens while enhancing the body’s natural immune response. What sets this IP is its utilization of a chimeric HSV backbone, which allows for improved viral gene expression. By expressing the neuroblastoma antigen (Phox2B) along with human IFNγ, the virus aims to upregulate MHCI associated with Phox2B antigens, thereby enhancing T cell activity against the tumor. This approach not only boosts the efficacy of CAR-T therapy but also stimulates native T cell responses, ultimately enhancing immune-mediated anti-tumor activity. The potential applications of this technology are wide-ranging. As a standalone therapy, it offers a promising treatment option for patients with neuroblastoma. When used in combination with CAR-T therapy, it holds the potential to significantly enhance anti-tumor activity, addressing a critical need in pediatric oncology. The IP is entering pre-clinical testing, with plans to assess its efficacy in conjunction with CAR-T cells at CHOP.